Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Recruiting · NCT06496048 · Registry updated 2024-12-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 3 | 2024-12-12 | NCT06496048 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Luye Pharma Group Ltd. | 14 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Jilin Provincial Tumor Hospital | Jilin City | China | 1 |